1
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
3
|
Mori R, Futamura M, Morimitsu K, Saigo C,
Miyazaki T and Yoshida K: The diagnosis of a metastatic breast
tumor from ovarian cancer by the succession of a p53 mutation: A
case report. World J Surg Oncol. 15:1172017. View Article : Google Scholar : PubMed/NCBI
|
4
|
Nakayama N, Nakayama K, Yeasmin S,
Ishibashi M, Katagiri A, Iida K, Fukumoto M and Miyazaki K: KRAS or
BRAF mutation status is a useful predictor of sensitivity to MEK
inhibition in ovarian cancer. Br J Cancer. 99:2020–2028. 2008.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Bennett MR and Clarke MC: Basic research:
Killing the old: Cell senescence in atherosclerosis. Nat Rev
Cardiol. 14:8–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Burgess DJ: Senescence: Double or quit?
Nat Rev Cancer. 11:3892011. View
Article : Google Scholar : PubMed/NCBI
|
7
|
Mathon NF and Lloyd AC: Cell senescence
and cancer. Nat Rev Cancer. 1:203–213. 2001. View Article : Google Scholar : PubMed/NCBI
|
8
|
Burgess DJ: Senescence: Tumorigenesis
under surveillance. Nat Rev Cancer. 12:62011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Visser JA, Schipper I, Laven JS and
Themmen AP: Anti-Mullerian hormone: An ovarian reserve marker in
primary ovarian insufficiency. Nat Rev Endocrinol. 8:331–341. 2012.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Nardella C, Clohessy JG, Alimonti A and
Pandolfi PP: Pro-senescence therapy for cancer treatment. Nat Rev
Cancer. 11:503–511. 2011. View
Article : Google Scholar : PubMed/NCBI
|
11
|
Campisi J and d'Adda di Fagagna F:
Cellular senescence: When bad things happen to good cells. Nat Rev
Mol Cell Biol. 8:729–740. 2007. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Killock D: Chemotherapy: Life gained,
years lost? Nat Rev Clin Oncol. 11:3032014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Collado M and Serrano M: Senescence in
tumours: Evidence from mice and humans. Nat Rev Cancer. 10:51–57.
2010. View
Article : Google Scholar : PubMed/NCBI
|
14
|
Li J, Mao Q, He J, She H, Zhang Z and Yin
C: Human umbilical cord mesenchymal stem cells improve the reserve
function of perimenopausal ovary via a paracrine mechanism. Stem
Cell Res Ther. 8:552017. View Article : Google Scholar : PubMed/NCBI
|
15
|
Mikuła-Pietrasik J, Uruski P, Pakuła M,
Maksin K, Szubert S, Woźniak A, Naumowicz E, Szpurek D, Tykarski A
and Książek K: Oxidative stress contributes to hepatocyte growth
factor-dependent pro-senescence activity of ovarian cancer cells.
Free Radic Biol Med. 110:270–279. 2017. View Article : Google Scholar : PubMed/NCBI
|
16
|
Jung EM, Choi KC and Jeung EB: Expression
of calbindin-D28k is inversely correlated with proapototic gene
expression in hydrogen peroxide-induced cell death in endometrial
cancer cells. Int J Oncol. 38:1059–1066. 2011.PubMed/NCBI
|
17
|
Goffigan-Holmes J, Sanabria D, Diaz J,
Flock D and Chavez-Valdez R: Calbindin-1 expression in the
hippocampus following neonatal hypoxia-ischemia and therapeutic
hypothermia and deficits in spatial memory. Dev Neurosci. March
12–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
18
|
Parkash J, Chaudhry MA and Rhoten WB:
Calbindin-D28k and calcium sensing receptor cooperate in MCF-7
human breast cancer cells. Int J Oncol. 24:1111–1119.
2004.PubMed/NCBI
|
19
|
Massouh M, Wallman MJ, Pourcher E and
Parent A: The fate of the large striatal interneurons expressing
calretinin in Huntington's disease. Neurosci Res. 62:216–224. 2008.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Cai Z, Qian ZY, Jiang H, Ma N, Li Z, Liu
LY, Ren XX, Shang YR, Wang JJ, Li JJ, et al: hPCL3s promotes
hepatocellular carcinoma metastasis by activating β-catenin
signaling. Cancer Res. 78:2536–2549. 2018. View Article : Google Scholar : PubMed/NCBI
|
21
|
Deng YZ, Yao F, Li JJ, Mao ZF, Hu PT, Long
LY, Li G, Ji XD, Shi S, Guan DX, et al: RACK1 suppresses gastric
tumorigenesis by stabilizing the β-catenin destruction complex.
Gastroenterology. 142:812–823.e15. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
23
|
Levine AJ: The p53 tumor suppressor gene
and gene product. Princess Takamatsu Symp. 20:221–230.
1989.PubMed/NCBI
|
24
|
Ohtani N, Mann DJ and Hara E: Cellular
senescence: Its role in tumor suppression and aging. Cancer Sci.
100:792–797. 2009. View Article : Google Scholar : PubMed/NCBI
|
25
|
Jin C, Lin T and Shan L: Downregulation of
Calbindin 1 by miR-454-3p suppresses cell proliferation in nonsmall
cell lung cancer in vitro. Cancer Biother Radiopharm. 34:119–127.
2019. View Article : Google Scholar : PubMed/NCBI
|
26
|
Yang F, von Knethen A and Brune B:
Modulation of nitric oxide-evoked apoptosis by the p53-downstream
target p21(WAF1/CIP1). J Leukoc Biol. 68:916–922. 2000.PubMed/NCBI
|
27
|
Labidi-Galy SI, Olivier T, Rodrigues M,
Ferraioli D, Derbel O, Bodmer A, Petignat P, Rak B, Chopin N,
Tredan O, et al: Location of mutation in BRCA2 gene and survival in
patients with ovarian cancer. Clin Cancer Res. 24:326–333. 2018.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Schuyer M, van Staveren IL, Klijn JG, vd
Burg ME, Stoter G, Henzen-Logmans SC, Foekens JA and Berns EM:
Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian
tumours. Br J Cancer. 74:1069–1073. 1996. View Article : Google Scholar : PubMed/NCBI
|